[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LU92684I2 - Fidaxomicine ou son sel pharmaceutiquement acceptable - Google Patents

Fidaxomicine ou son sel pharmaceutiquement acceptable Download PDF

Info

Publication number
LU92684I2
LU92684I2 LU92684C LU92684C LU92684I2 LU 92684 I2 LU92684 I2 LU 92684I2 LU 92684 C LU92684 C LU 92684C LU 92684 C LU92684 C LU 92684C LU 92684 I2 LU92684 I2 LU 92684I2
Authority
LU
Luxembourg
Prior art keywords
ifadxomicin
pharmaceutically acceptable
acceptable salt
salt
pharmaceutically
Prior art date
Application number
LU92684C
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LU92684I2 publication Critical patent/LU92684I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
LU92684C 2002-07-29 2015-03-26 Fidaxomicine ou son sel pharmaceutiquement acceptable LU92684I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39995602P 2002-07-29 2002-07-29

Publications (1)

Publication Number Publication Date
LU92684I2 true LU92684I2 (fr) 2015-11-02

Family

ID=31715689

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92684C LU92684I2 (fr) 2002-07-29 2015-03-26 Fidaxomicine ou son sel pharmaceutiquement acceptable

Country Status (18)

Country Link
US (4) US7507564B2 (fr)
EP (2) EP2860241A1 (fr)
JP (3) JP2005534332A (fr)
KR (1) KR100972542B1 (fr)
CN (1) CN100519757C (fr)
AU (1) AU2003251902B2 (fr)
BE (1) BE2015C017I2 (fr)
CA (1) CA2494742C (fr)
CY (1) CY2015015I1 (fr)
DK (1) DK1539977T3 (fr)
ES (1) ES2527052T3 (fr)
FR (1) FR15C0028I2 (fr)
HU (1) HUS1500016I1 (fr)
LU (1) LU92684I2 (fr)
NL (1) NL300727I2 (fr)
PT (1) PT1539977E (fr)
SI (1) SI1539977T1 (fr)
WO (1) WO2004014295A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1539977E (pt) * 2002-07-29 2015-01-14 Optimer Pharmaceuticals Inc Produção de tiacumicina
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
JP5734545B2 (ja) * 2004-05-14 2015-06-17 オプティマー ファーマシューティカルズ、インコーポレイテッド 抗生物質の使用に関連する疾患の治療
AU2005327308B2 (en) * 2005-01-31 2011-11-10 Merck Sharp & Dohme Llc 18-membered macrocycles and analogs thereof
AU2012200784B2 (en) * 2005-01-31 2013-07-11 Merck Sharp & Dohme Llc 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
CA2626698C (fr) * 2005-10-21 2015-12-01 Optimer Pharmaceuticals, Inc. Methode de traitement d'une diarrhee associee a clostridium difficile
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
KR100891313B1 (ko) * 2007-08-17 2009-03-31 (주) 제노텍 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
TWI326284B (en) * 2007-10-26 2010-06-21 Echem Hightech Co Ltd Derivatives of tiacumicin b as anti-cancer agents
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
EP2545023A4 (fr) * 2010-02-15 2017-04-12 Abbvie Inc. Procédé de préparation de scyllo-inositol
CN103402954A (zh) 2010-10-13 2013-11-20 依兰制药公司 鲨肌醇和相关化合物的合成方法
CN102115757B (zh) * 2010-12-14 2015-10-28 中国科学院南海海洋研究所 台勾霉素的生物合成基因簇及其应用
ITMI20120559A1 (it) * 2012-04-05 2013-10-06 Olon Spa Procedimento migliorato per la produzione di tiacumicina b
ITMI20120560A1 (it) * 2012-04-05 2013-10-06 Olon Spa Procedimento per la purificazione della tiacumicina b
CN104768963A (zh) * 2012-05-10 2015-07-08 特瓦制药厂有限公司 非达霉素的固态形式及其制备方法
CA2881302C (fr) 2012-08-07 2020-12-15 Olon S.P.A. Procedure pour la production de tiacumicine b
ITMI20121406A1 (it) * 2012-08-07 2014-02-08 Olon Spa Procedimento per la produzione di tiacumicina b
ITMI20130856A1 (it) * 2013-05-27 2014-11-28 Olon Spa Procedimento per la produzione di tiacumicina b
CN102993251B (zh) * 2012-12-17 2016-03-16 苏州纳微科技有限公司 一种用高效液相色谱纯化台勾霉素b的方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
WO2014174528A2 (fr) * 2013-04-23 2014-10-30 Concord Biotech Limited Procédé perfectionné de préparation de la fidaxomicine
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103275153B (zh) * 2013-06-27 2016-03-23 华北制药集团新药研究开发有限责任公司 一种非达霉素晶体的制备方法
CN104418925B (zh) * 2013-09-05 2018-09-28 重庆乾泰生物医药有限公司 一种制备高纯度非达霉素的方法
CN104513286B (zh) * 2013-09-27 2018-08-17 博瑞生物医药（苏州）股份有限公司 一种分离纯化非达米星的方法
CN104560766B (zh) * 2013-10-16 2017-07-28 浙江海正药业股份有限公司 一种游动放线菌菌株及其应用
CN104561198B (zh) * 2013-10-18 2019-04-12 重庆乾泰生物医药有限公司 一种发酵生产非达霉素的方法
CN106164283A (zh) 2013-12-20 2016-11-23 赛利亚医药公司 制备台勾霉素的方法
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
WO2015127955A1 (fr) 2014-02-25 2015-09-03 Olon S.P.A. Nouvelle forme polymorphe de tiacumicine b et son procede de preparation
BR112016021542B1 (pt) 2014-03-18 2023-01-31 Xellia Pharmaceuticals Aps Novos polimorfos e novos estados sólidos de tiacumicina b
CN104946708B (zh) * 2014-03-28 2018-06-12 上海医药工业研究院 一种生产非达霉素的发酵培养基以及发酵方法
CN103880904B (zh) * 2014-03-28 2016-08-24 华北制药集团新药研究开发有限责任公司 非达霉素晶型i及其制备方法
PL3139932T3 (pl) 2014-05-09 2019-02-28 Astellas Pharma Europe Ltd. Schemat leczenia dla związku-tiakumycyny
CN104098637B (zh) * 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法
WO2017005358A1 (fr) 2015-07-03 2017-01-12 Astellas Pharma Europe Ltd. Nouveau composé de tiacumicine pour régime posologique
IL251499B (en) * 2017-04-02 2019-02-28 Efraty Avi Reverse osmosis installation in a closed circuit with a hydraulic arm for desalination with low energy consumption and a high recovery ratio
CN107236686B (zh) * 2017-06-21 2019-10-15 杭州华东医药集团新药研究院有限公司 一种桔橙指孢囊菌及其在调控微生物代谢物非达霉素中的应用
CN114084964B (zh) * 2020-08-24 2023-02-24 中国石油化工股份有限公司 一种芳香有机化合物废水生物处理促进剂及制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3000792A (en) 1957-05-21 1961-09-19 Merck & Co Inc Antibiotic adsorption process
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4632902A (en) * 1981-08-20 1986-12-30 Becton, Dickinson And Company Method for detecting biological activity in a body fluid
US4843008A (en) * 1984-12-24 1989-06-27 Yamanouchi Pharmaceutical Co., Ltd. Novel microorganisms and a novel process for producing antibiotics
US4918174A (en) * 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5242815A (en) * 1990-01-24 1993-09-07 Shin-Etsu Chemical Co., Ltd. Process for preparation of streptovaricin
CA2384523C (fr) * 1991-03-04 2007-01-09 Bayer Corporation Analyseur automatise
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
CN1196698C (zh) * 1996-11-18 2005-04-13 生物技术研究有限公司(Gbf) Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
JP2000072760A (ja) * 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) * 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) * 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
NZ546497A (en) * 2000-04-28 2008-04-30 Kosan Biosciences Inc Production of polyketides
PT1539977E (pt) * 2002-07-29 2015-01-14 Optimer Pharmaceuticals Inc Produção de tiacumicina

Also Published As

Publication number Publication date
FR15C0028I2 (fr) 2015-11-13
WO2004014295A3 (fr) 2005-04-14
WO2004014295A2 (fr) 2004-02-19
SI1539977T1 (sl) 2015-01-30
EP1539977B1 (fr) 2014-10-08
CN100519757C (zh) 2009-07-29
NL300727I2 (fr) 2016-05-17
BE2015C017I2 (fr) 2022-09-22
EP1539977A2 (fr) 2005-06-15
JP2013208131A (ja) 2013-10-10
US7507564B2 (en) 2009-03-24
KR20050053598A (ko) 2005-06-08
US20060257981A1 (en) 2006-11-16
JP5729919B2 (ja) 2015-06-03
CN1688707A (zh) 2005-10-26
PT1539977E (pt) 2015-01-14
JP2010178760A (ja) 2010-08-19
AU2003251902B2 (en) 2008-03-06
CA2494742C (fr) 2015-05-12
FR15C0028I1 (fr) 2015-05-15
EP1539977A4 (fr) 2006-10-11
KR100972542B1 (ko) 2010-07-28
CY2015015I1 (el) 2020-05-29
JP5907931B2 (ja) 2016-04-26
HUS1500016I1 (hu) 2017-10-30
ES2527052T3 (es) 2015-01-20
US20130123477A1 (en) 2013-05-16
JP2005534332A (ja) 2005-11-17
US8728796B2 (en) 2014-05-20
US20100028970A1 (en) 2010-02-04
CA2494742A1 (fr) 2004-02-19
AU2003251902A1 (en) 2004-02-25
DK1539977T3 (en) 2014-11-17
US20140296498A1 (en) 2014-10-02
EP2860241A1 (fr) 2015-04-15

Similar Documents

Publication Publication Date Title
LU92684I2 (fr) Fidaxomicine ou son sel pharmaceutiquement acceptable
FR19C1072I2 (fr) Derive de 2-acylaminothiazole et son sel
LU92702I2 (fr) Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig)
NO20052914D0 (no) Terapeutiske forbindelser
DK1704324T3 (da) Leddelt falsk havbund
DE60333537D1 (de) Herzschrittmacher
DE60317391D1 (de) Verbinder
SE0203705L (sv) Vinkelhake
NO20044046L (no) Substituerte hydroksyetylaminer
DE60326590D1 (de) Tend lamotrigin
DE60301239D1 (de) Verbinder
DE60208885D1 (de) Verbinder
DE60315937D1 (de) Verbinder
DE50310014D1 (de) Mähbalken
DK1482936T3 (da) Öjenpræparat omfattende ascomycin
DE60223352D1 (de) Verbinder
DE50313263D1 (de) Erntemaschine
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
NL1024677A1 (nl) Therapeutische prolinederivaten.
DE60319512D1 (de) Drehgelenk
DE10301279B8 (de) Verbinder
DE60312105D1 (de) Verbinder
DE60218623D1 (de) Verbinder
DE50307081D1 (de) Gabelbrücke
DE60328488D1 (de) Ng